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OBJECTIVE—To determine whether delaying the introduction of gluten in infants with a
genetic risk of islet autoimmunity is feasible, safe, and may reduce the risk of type 1 diabetes–
associated islet autoimmunity.
RESEARCH DESIGNAND METHODS—Atotalof 150infantswith aﬁrst-degree family
history of type 1 diabetes and a risk HLA genotype were randomly assigned to a ﬁrst gluten
exposureatage6months(controlgroup)or12months(late-exposuregroup)andwerefollowed
3 monthly until the age of 3 years and yearly thereafter for safety (for growth and autoantibodies
to transglutaminase C [TGCAs]), islet autoantibodies to insulin, GAD, insulinoma-associated
protein 2, and type 1 diabetes.
RESULTS—Adherencetothedietary-interventionprotocolwasreportedfrom70%offamilies.
During the ﬁrst 3 years, weight and height were similar in children in the control and late-
exposure groups, as was the probability of developing TGCAs (14 vs. 4%; P =0 . 1 ) .E l e v e n
children in the control group and 13 children in the late-exposure group developed islet auto-
antibodies(3-yearrisk:12vs.13%;P=0.6).Sevenchildrendevelopeddiabetes,includingfourin
the late-exposure group. No signiﬁcant differences were observed when children were analyzed
as per protocol on the basis of the reported ﬁrst gluten exposure of the children.
CONCLUSIONS—Delaying gluten exposure until the age of 12 months is safe but does not
substantially reduce the risk for islet autoimmunity in genetically at-risk children.
Diabetes Care 34:1301–1305, 2011
T
ype 1 diabetes is an autoimmune
diseasewithapreclinicalphasechar-
acterized by the presence of islet
autoantibodies (1). Genetic susceptibility
for islet autoimmunity is well documented
(2), and environmental factors are as-
sumed to modify the genetically deﬁned
risk of developing islet autoantibodies
(1,3).
Data from mouse models of auto-
immunediabetessupportaroleforgluten
in modifying autoimmune diabetes risk,
with deprivation of gluten or even de-
layed introduction resulting in later and
less frequent development of diabetes
(4,5). In humans, prospective studies
(6,7) show that the age at introduction
of solid food, such as gluten-containing
foods or cereals, affects the development
of islet autoimmunity in children who are
genetically susceptible to type 1 diabetes.
Two studies report increased risk of islet
autoimmunityinchildrenwhoareexposed
to gluten before the 4th month, and one of
thestudiesalsodemonstratesincreasedrisk
when gluten exposure is delayed beyond
age6months(6,7).Furthermore,interven-
tioninisletautoantibody–positivechildren
indicates that b-cell function may be im-
proved by a deprivation of gluten for
6 months (8). Gluten is a driving antigen
of celiac disease. There is no association
between early gluten exposure and risk
for autoantibodies to transglutaminase C
(TGCAs), which is a marker of celiac dis-
ease (9,10), but one study reports an in-
creased risk for TGCAs in children who
were ﬁrst exposed to cereals after the age
of 7 months (10).
We performed a dietary primary pilot
intervention study to determine whether
delaying the introduction of gluten to the
diet may be beneﬁcialin reducing the risk
oftype1diabetes–associatedisletautoim-
munity in children with a predetermined
genetic risk of islet autoimmunity, which
was ~15% of children (11). We speciﬁ-
cally assessed the feasibility of such an
intervention, the safety with respect to
growth, the development of gluten-
driven celiac disease, and, as a pilot efﬁ-
cacy measure, the cumulative frequency
of islet autoimmunity by age 3 years.
RESEARCH DESIGN AND
METHODS
Eligibility criteria
Children from Germany were eligible to
participate in the BABYDIET study if they
were younger than 2 months of age, not
yetexposedtogluten,andhadatleasttwo
ﬁrst-degree relatives with type 1 diabetes
or one ﬁrst-degree relative with type 1
diabetes and one of the following type 1
diabetes–associated HLA genotypes:
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Written informed consent for genetic
screening as well as for enrollment into
the intervention trial was provided by the
infant’s primary caretakers. Infants were
excluded from the study if they had an
illness or birth defect that precludes
long-term follow-up. After inclusion,
children were followed in 3-monthly in-
tervals until the age of 3 years and yearly
thereafterforefﬁcacyandsafetyassessment.
The trial was conducted at the Diabetes
Research Institute (Munich, Germany)
and was approved by the ethics committee
of the Ludwig-Maximilian University,
Munich, Germany (Ethikkommission
der Medizinischen Fakultät der Ludwig-
Maximilians Universität no. 329/00).
Intervention
Children were randomly assigned to be
introduced to gluten at the age of 6 months
(n = 77, control group), which corre-
sponds to the national recommendations
for early infant feeding, or to delay the in-
troduction of gluten until the age of 12
months (n = 73, late-exposure group).
Random assignment was performed in-
dependently using the minimization
method and included stratiﬁcation for
HLA genotype, a family member with type
1 diabetes, and the sex of the participating
child to achieve balance between both
groups. At inclusion, each participating
family was visited by a nutritionist who
explained the gluten-free diet. Lists of
the most common foods introduced dur-
ingtheﬁrstyearoflifewereexamined,and
gluten-containing products were indi-
cated. Details of gluten-free commercial
infant products were provided to the pa-
rents. Until the age of 1.5 years, daily food
records were used to assess compliance to
the intervention, to estimate the dose of
gluten at ﬁrst exposure, and to record
theageatintroductionofotherfooditems.
Safety parameters
Safety parameters included the analysis of
celiacdisease–associatedIgAautoantibodies
to tTGCA and data on growth (height and
weight).tTGCAsweredeterminedinsam-
ples at the age of 6, 12, 18, 24, 30, and 36
months and yearly thereafter. Positivity
was deﬁned as positive for tTGCAs in
two consecutive samples. Data on weight
andheightwereobtainedattheageof3,6,
12,24,and36monthsbyaphysiciandur-
ing the clinical study visit.
End-point assessment
The primary end point was the develop-
ment of persistent autoantibodies to one
ormoreoftheantigensinsulin,GAD65or
insulinoma-associated protein 2 (IA-2A).
Persistence was deﬁned as being positive
in at least two consecutive samples and in
the last available sample. Islet autoanti-
bodies were measured in venous blood
samples from all scheduled visits. Diabetes
development was monitored and diag-
nosed according to the American Diabetes
AssociationExpertCommitteecriteria(12).
Confounding variables
Data on breastfeeding (yes or no), the
duration of breastfeeding (weeks), and
theintroductionofsolidfood(gluten-free
andgluten-containingcereals,vegetables,
and fruits) were taken from daily food re-
cords completed by the child’s parents.
Laboratory testing
HLA-DRB1, HLA-DQA1,a n dHLA-DQB1
were determined using PCR-ampliﬁed
DNAandnonradioactivesequence-speciﬁc
oligonucleotide probes, as described pre-
viously(13).Isletautoantibodiesandanti-
bodies to tissue transglutaminase also
were measured, as described previously.
Insulin autoantibodies (IAAs) were mea-
sured by protein A/G-radiobinding assays
using
125I-labeled recombinant human
insulin labeled at tyrosine aa 14 (14), and
GADantibodiesandinsulinoma-associated
protein 2 antigens (IA-2As) were mea-
sured by protein A radiobinding assays
using [35S]methionine-labeled in vitro
transcribed/translated recombinant anti-
g e n( 1 5 ) .t T G C A sw e r em e a s u r e du s i n g
theenzyme-linkedimmunosorbentassay
(Eurospital, Trieste, Italy) and conﬁrmed
by the radiobinding assay (9). Samples
with values above the 99th percentile of
control childrenweredeﬁnedaspositive.
Theinterassaycoefﬁcientofvariationval-
u e sf o rs a m p l e sw i t hl o wa u t o a n t i b o d y
levels were 11% (IAAs), 18% (GAD anti-
bodies), and 16% (IA-2As).
Statistical analysis
The study was designed to primarily test
the feasibility of a dietary-intervention
study in infants at high genetic risk for
isletautoimmunityandtype1diabetes.The
study was not powered to examine efﬁcacy
other than for major differences between
intervention and control groups. With the
assumption that 15% of the control group
will develop islet autoantibodies and 8%
will develop tTGCAs, the power of the
study was 40% to detect a halving of the
probability for islet autoantibodies (a =
0.05) and 45% to detect a doubling of the
tTGCA autoantibody probability.
The probability of developing islet
autoantibodies or tTGCAs was estimated
by Kaplan-Meier analysis. Hazards ratios
(HRs) were determined using the Cox
proportional hazards model. The age of
onset of islet autoantibodies or tTGCA
positivitywasdeﬁnedastheageattheﬁrst
positive sample. Groups were compared
on the intention-to-treat principle (con-
trol versus late-exposure groups), as well
as according to the true gluten exposure
date by per-protocol principle using the
followingcategories:ﬁrstglutenexposure
between 4.5and7.4versus10.5and13.5
months or by using age at ﬁrst gluten
exposure (months) as a continuous vari-
able. HRs were adjusted for the following
confounding variables: 1) duration of
breastfeeding (0–3.0 vs. .3.0 months);
2) still breastfeeding at ﬁrst gluten expo-
sure(yesorno);3)a geatﬁrst exposure to
solid food (#5.5 vs. .5.5 months); and
4) number of days with gluten exposure
in the 4 weeks after the ﬁrst gluten expo-
sure (,13 vs. $13 days). All P values
were two-tailed. Statistical analyses were
performed using the Statistical Package
for Social Science (PASW Statistics 18.0;
SPSS, Inc., Chicago, IL).
RESULTS
Feasibility and compliance
Between 2000 and 2006, 1,168 offspring
orsiblingsofpatientswithtype1diabetes
were screened for eligibility (Fig. 1). Of
those, 169 were eligible and 150 agreed
to participate in the study and were ran-
domly assigned to the control (n = 77) or
late-exposure (n = 73) groups. Subject
characteristics are shown in Supplementary
Table 1.
Of 150 participating children, 120
(63 control group children and 57 late-
exposure group children) completed the
follow-up to at least age 3 years or had
reached the study end point (persistent
isletautoantibody-positive)beforetheage
of 3 years (follow-up range 3.0–10.0).
Eight children (three in the control group
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drew from the study during the interven-
tion period (up to12 months of age).
The age at ﬁrst gluten exposure was
provided for 140 children (68 children
from the late-exposure group and 72
children from the control group). The
overallmedianageofglutenexposurewas
10.0 and 7.0 months (interquartile range
6.0–9.9) for those in the control group
and 11.9 months (10.8–12.0) for those
in the late-exposure group (P , 0.0001)
(Fig. 2A). A total of 23 (32%) children in
the control group were not introduced to
gluten within the speciﬁed time interval
of 4.5–7.5 months (4 were introduced to
gluten earlier, and 19 were introduced
later), and 18 (26%) children in the late-
exposure group were not introduced to
gluten in the speciﬁed 10.5- to 13.5-
month time interval (15 were introduced
to gluten earlier, and 3 were introduced
later). Data on the age at introduction of
any solid food and the duration of full
breastfeeding were available in 136 and
144 children, respectively (Fig. 2B and C).
The age of introducing solid food was sim-
ilarinthecontrol(median5.8months)and
late-exposure (median 5.6 months)
groups (P = 0.65). The median duration
of full breastfeeding was 2 weeks (inter-
quartile range 0–22) in the control group
and 10 weeks (0–25) in the late-exposure
group (P = 0.09).
Safety assessments
Effect of delayed gluten introduction
on celiac disease–associated tTGCAs. By
the age of 3 years, eight children in the
control group and three children in the
late-exposuregroupdevelopedpersistent
tTGCAs. The cumulative risk of develop-
ing tTGCAs at age 3 years was 14% (95%
CI4.2–23.8)inthecontrolgroupand4%
(0.1–9.9; P = 0.1) in the late-exposure
group (Fig. 3A). An additional six chil-
dren developed tTGCAs after age 3 years
(two children in the control group and
four in the late-exposure group). Three
o ft h et T G C A - p o s i t i v ec h i l d r e no ft h e
control group underwent a biopsy, and
celiac disease was diagnosed in two of
them. In the late-exposure group, four
children had a biopsy and all had celiac
disease.
Effect of delayed gluten introduction
on growth. The development of height
and weight during the ﬁrst 3 years of life
did not differ between the control and
late-exposure groups (Fig. 3B). Weight
gain during the ﬁrst year of life (control
group: 5,630 g vs. late-exposure group:
5,640 g; P =0 . 6 )a n df r o ma g e1 2t o4 8
months (control group: 7,070 g vs. late-
exposure group 7,230 g; P =0 . 9 )w a s
comparable between groups. The preva-
lence of overweight (BMI percentile $90
as determined by the German reference
system [16]) was similar between groups
(age 2 years: 4 of 56 children in the con-
t r o lg r o u pv s .4o f4 9c h i l d r e ni nt h el a t e -
exposuregroup;P=1.0;datanotshown).
Effect of delayed gluten introduction
on islet autoimmunity outcome and type
1 diabetes: intention-to-treat analysis. A
total of 16 children developed islet auto-
antibodiesduringtheﬁrst3years,includ-
ing 8 in the control group and 8 in the
late-exposure group; 11 of 16 children
developed more than one islet autoanti-
body (6 in the control group and 5 in the
late-exposure group). An additional eight
children developed islet autoantibodies
aftertheageof3years(ﬁvechildreninthe
late-exposure group). Six children devel-
oped autoantibodies prior to their ﬁrst
reported gluten exposure. The probabil-
ity of developing any islet autoantibody
(IAAs,GADantibodies,and/orIA-2As)by
the age of 3 years in the total cohort was
12% (95% CI 6.1–17.9) and was 12% in
the control (4.2–19.8) and 13% in the
late-exposure (5.2–20.8; P = 0.6) groups
(Fig. 4A). The probability of developing
multiple islet autoantibodies also was
similar between groups (control group:
9.0% by age 3 years; late-exposure group:
Figure 1—Flowchart of the BABYDIET study population.
Figure 2—Age at ﬁrst exposure to (A) gluten-containing food, (B) any solid food, and (C) full
breastfeeding duration in children randomly assigned to the late-exposure and control groups.
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Hummel and Associates8.0%; P = 0.7) (Fig. 4B), as was the prob-
ability of developing IAAs and GAD anti-
bodies (Supplementary Fig. 1). The
adjustedHR fordevelopingislet autoanti-
bodies was 1.3 (95% CI 0.6–3.0) for the
late-exposure group after adjusting for
confounding variables (breastfeeding du-
ration, breastfeeding during ﬁrst gluten
exposure, introduction of solid food,
and gluten dosage after the ﬁrst expo-
sure). Seven children developed diabetes
(threeinthecontrolgroupandfourinthe
late-exposure group).
Per-protocol analysis. Approximately
30% of families did not follow protocol
guidelines and introduced gluten outside
the time period assigned by randomiza-
tion. We therefore analyzed the risk to
develop islet autoantibodies and tTGCAs
accordingtothereportedglutenexposure
age (Supplementary Fig. 2A and B). Chil-
drenwhowereexposedtoglutenbetween
10.5 and 13.5 months of age (n = 63)
had a similar 3-year islet autoantibody
risk (12%) compared with children who
were exposed to gluten between 4.5 and
7.5 months of age (n = 44; 13%; P =0 . 7 ) .
tTGCA risk by 3 years also was nonsignif-
icantly different in children exposed
to gluten late (6%) versus early (18%;
P = 0.08). When age at ﬁrst gluten expo-
sure was considered as a continuous vari-
able, the age at gluten exposure did not
inﬂuencetheprobabilityofdevelopingislet
autoantibodies(per month delayingluten
exposure: HR 1.08 [95% CI 0.9–1.3];
P = 0.4) or tTGCAs (0.92 [0.73–1.16];
P =0 . 5 ) .
CONCLUSIONS—The BABYDIET
study is a pilot study to determine
whether delaying the introduction of
gluten to the diet of neonates until 12
months of age is a feasible strategy to
reduce the risk of islet autoimmunity in
childrenwithahighgeneticriskfortype1
diabetes. The study found that 30% of
families reported that they did not adhere
to the gluten introduction protocol for
their randomization group. Nevertheless,
late gluten introduction, whether by ran-
domization group or as reported by fam-
ilies, did not increase the risk for tTGCAs
and did not affect growth, suggesting that
itisrelativelysafe.Althoughthestudywas
not powered to examine efﬁcacy other
than for major differences between inter-
vention and control groups, the number
of islet autoantibody–positive children
and the number of cases of diabetes in
the late-exposure group and the control
group were very similar. These data sug-
gest that delaying gluten exposure until
the age of 12 months is safe but will not
substantially reduce the prevalence of is-
let autoimmunity in genetically at-risk
children.
Previous observations showed an in-
creased risk of islet autoimmunity when
gluten-containing cereals (6) or any cere-
als (7) were introduced during the ﬁrst 3
months of life in children with increased
genetic risk for type 1 diabetes. Because
Germany and many other countries rec-
ommend introducing gluten at 6 months
ofage,wewereunabletodesignastudyto
formally compare intervention with 3
months versus later gluten introduction.
Hence, our design was to extend the
gluten-free exposure to 12 months of age.
Recruitment was not problematic,with the
majority of eligible families consenting to
participate in the intervention. Retention,
despite the intensive follow-up of the pro-
tocol, also was high (80%). Families were
well instructed as to the foods that contain
gluten.Inaddition,studymemberswerein
contact with families weekly to discuss is-
sues related to feeding during the study.
However, randomization was not blinded,
and ~30% of families did not adhere to the
protocol for their assigned randomization
Figure 3—Safety assessments. A: Probability of tTGCAs by Kaplan-Meier analysis in offspring
randomlyassignedto theBABYDIET late-exposuregroup(solidline)and the BABYDIET control
group (broken line). B: Height (centimeters) and weight (kilograms) development from birth to
36 months of age in offspring randomly assigned to the BABYDIET late-exposure group (solid
line) and the BABYDIET control group (broken line).
Figure 4—Outcome analysis. Probability of (A) any islet autoantibody (IAAs, GAD antibodies,
and/or IA-2As) and (B) multiple islet autoantibody frequency by Kaplan-Meier analysis in off-
spring randomly assigned to the BABYDIET late-exposure group (solid line) and the BABYDIET
control group (broken line).
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was attributed to families opting for a de-
layed gluten introduction, potentially as a
result of the perceived positive effects of
interventionovercontrol.Thus,dietary in-
tervention in early infancy appears feasible
but will likely be affected by a relatively
high rate of noncompliance, unless blind-
ing of diet is possible.
Safety was a potential issue in the
current study because previous reports
had suggested a link between delayed
gluten introduction and an increase in
celiac disease incidence (17). Moreover,
and in contrast to our previous ﬁndings
(6,9),theDAISY(DiabetesAutoimmunity
Study in the Young) study found that de-
laying gluten introduction to later than
age 7 months was associated with an in-
creaseintheriskfortTGCAs(10)andislet
autoantibodies (7). Our current study
found no increase in tTGCA risk in chil-
drenofthelate-exposuregroupalsowhen
the analysis was performed on a per-
protocol basis. Indeed, although not sig-
niﬁcant, the risk of tTGCAs in children
within the late-exposure group was
around one-third that of children in the
control group. Growth also was unaf-
fected by the intervention. Thus, we con-
cludethatdelayofglutentothedietissafe
and we cannot conﬁrm previous ﬁndings
suggesting that it will increase the risk for
celiac disease.
We found no evidence of a beneﬁt
with respect to reducing the risk for islet
autoantibodies. Similar to the TRIGR
(Trial to Reduce Insulin-Dependent Di-
abetes Mellitus in the Genetically at Risk)
pilotstudy(18),theBABYDIETstudywas
not powered for efﬁcacy. The power of
the study was ~40% to detect a 50% re-
duction in the probability of islet auto-
antibodies. Increasing the power to 80%
would require at least three times the
number of participants, and in view of
the difﬁculty with compliance, it appears
justiﬁed to have conducted a pilot feasi-
bility study ﬁrst. Nevertheless, even with
the limited power of the study, we do not
recommend altering current pediatric
guidelines with respect to the introduction
of gluten into the diet of children who are
genetically at risk for type 1 diabetes.
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